Wengeng Liu

Title: Wengeng Liu: Innovator in ErbB/BTK Inhibitors

Introduction

Wengeng Liu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit ErbB and BTK proteins. His work is crucial in the fight against diseases associated with these proteins, including various forms of cancer.

Latest Patents

Wengeng Liu holds 3 patents related to ErbB/BTK inhibitors. These patents disclose compounds that inhibit ErbBs, such as EGFR or Her 2, especially their mutant forms, as well as BTK. The patents also cover pharmaceutically acceptable salts, hydrates, solvates, or stereoisomers of these compounds, along with pharmaceutical compositions that can effectively treat diseases associated with ErbBs and BTK.

Career Highlights

Throughout his career, Wengeng Liu has worked with notable companies, including Dizal Pharmaceutical Co., Ltd. and Dizal Pharmaceutical Co., Limited. His expertise in the pharmaceutical industry has allowed him to focus on innovative solutions for complex medical challenges.

Collaborations

Wengeng Liu has collaborated with several professionals in his field, including Zhengtao Li and Hao Zou. These collaborations have further enhanced his research and development efforts in the pharmaceutical sector.

Conclusion

Wengeng Liu's contributions to the field of ErbB/BTK inhibitors highlight his role as an influential inventor in the pharmaceutical industry. His innovative work continues to pave the way for advancements in cancer treatment and other related diseases.